» Articles » PMID: 16186325

Monosomy 3 Predicts Death but Not Time Until Death in Choroidal Melanoma

Overview
Specialty Ophthalmology
Date 2005 Sep 28
PMID 16186325
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: To study whether monosomy 3 can predict time until death caused by metastatic melanoma, whether life expectancy can be predicted in patients after surgical excision of a melanoma displaying monosomy 3, and to confirm the prognostic value of monosomy 3 and its correlation with tumor histology.

Methods: Archival specimens from 71 patients who died of metastatic melanoma and 40 patients who were living or had died of other causes were identified. The number of copies of chromosome 3 was assessed by chromosome in situ hybridization, and monosomy 3 was compared with clinicopathologic features.

Results: Monosomy 3 was detected in 47 of 71 metastasizing melanomas (66.1%) and was significantly associated with metastasis-related death (P < 0.0001). All 40 nonmetastasizing tumors were balanced for chromosome 3 (two copies). In 70% of cases, epithelioid cells and vascular loops in combination predicted the presence of monosomy 3 (P < 0.0001). Among the 71 patients who had died of metastasizing melanoma, there was no difference in time until death between monosomic and balanced tumors. However, a survival curve corrected for age of the patients at the time of surgery suggested that very-long-term survival with monosomy 3 is probably rare.

Conclusions: Monosomy 3 is an important predictor of death in melanoma and is in some cases predicted by histology. However, death of metastatic disease occurs in a significant number of patients without monosomy 3. There is no significant difference in time until death between metastatic melanomas, with and without monosomy 3. However, survival of patients with tumors displaying monosomy 3 is generally short.

Citing Articles

A Predictive Web-Based Nomogram for Elderly Patients Newly Diagnosed as Uveal Melanoma: A Population-Based Study.

Lv M, Yan X, Tu Y Front Med (Lausanne). 2022; 9:799083.

PMID: 35814753 PMC: 9259836. DOI: 10.3389/fmed.2022.799083.


Nation-Wide Trends in Incidence-Based Mortality of Patients with Ocular Melanoma in USA: 2000 to 2018.

Valasapalli S, Guddati A Int J Gen Med. 2021; 14:4171-4176.

PMID: 34385837 PMC: 8354021. DOI: 10.2147/IJGM.S299144.


Prognostic Factors Five Years After Enucleation for Uveal Melanoma.

Dogrusoz M, Brouwer N, de Geus S, Ly L, Bohringer S, van Duinen S Invest Ophthalmol Vis Sci. 2020; 61(3):31.

PMID: 32186672 PMC: 7401572. DOI: 10.1167/iovs.61.3.31.


Surgery vs. radiotherapy in patients with uveal melanoma : Analysis of the SEER database using propensity score matching and weighting.

Jang B, Chang J, Oh S, Lim Y, Kim I Strahlenther Onkol. 2017; 193(11):931-942.

PMID: 28879443 DOI: 10.1007/s00066-017-1203-0.


Atypical Presentation: Metastatic Uveal Melanoma in a Young Patient without Visual Complaints.

Buiar P, de Azevedo S Front Oncol. 2017; 7:99.

PMID: 28573105 PMC: 5435810. DOI: 10.3389/fonc.2017.00099.